Background: Direct oral anticoagulants are convenient because of their fixed dosing and without laboratory monitoring. There are instructions on avoidance of moisture, no crushing of capsules, and administration with food for some direct oral anticoagulants. Whether patients adhere to this and are prescribed appropriate doses are unknown. Aims: To assess direct oral anticoagulant dosing and medication use. Methods: Patients 518 years old, receiving a direct oral anticoagulant for any diagnosis, were prospectively included. Nurses at our perioperative anticoagulation clinic helped patients complete a 12-item questionnaire. Results: Ninety-three consecutive patients were recruited. Forty-nine were on dabigatran, 18 on apixaban, and 26 were on rivaroxaban. Sixty-two patients (67%) received appropriate direct oral anticoagulant dosing and administered the medication correctly. Eighteen patients (19%) administered the direct oral anticoagulant properly but at an inappropriate dose. Thirteen patients (14%) received an appropriate dose but administered the direct oral anticoagulant inappropriately: 10 (11%) removed dabigatran from its packaging before administration (exposing it to moisture); 2 (2%) did not take rivaroxaban with food; and 1 (1%) crushed the dabigatran capsule. Conclusion: Our study demonstrates a large variability in how direct oral anticoagulants are dosed, and how patients take them. Improved medication literacy around direct oral anticoagulants is needed. Our study highlights opportunities that nurses have to improve patients' medication literacy.
Direct oral anticoagulants (DOACs) have been shown to be as effective as conventional therapy with vitamin K antagonists (VKAs) in the prevention of stroke in atrial fibrillation and treatment and secondary prevention of venous thromboembolism (VTE), in both randomized clinical trials and ''real-world'' post marketing surveillance studies (Agnelli et al., 2013; Connolly et al., 2009; EINSTEIN Investigators, 2010; EINSTEIN-PE Investigators, 2012; Granger et al., 2011; Hokusai-VTE Investigators, 2013; Larsen et al., 2013; Lip et al., 2016; Patel et al., 2011; Schulman et al., 2009) . As a result, the American College of Chest Physician guidelines issued a recommendation in favor of DOACs over VKAs for acute and long-term treatment of VTE in patients without cancer (Kearon et al., 2016) . Hence, clinicians worldwide may be more inclined to prescribe DOACs for VTE than VKAs.
The four available DOACs in Canada are dabigatran (a direct thrombin inhibitor), apixaban, rivaroxaban, and edoxaban (all direct factor Xa inhibitors). All four have been approved by the Health Canada for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment and secondary prevention of VTE. The DOACs come with specific manufacturer's recommendations with regard to storage and administration. Dabigatran must be kept in its original packaging and not stored in dosettes; if it is exposed to moisture, it will break down and lose its potency (FDA Drug Safety Communication, 2011; Pradaxa (Dabigatran Etexilate Mesylate) prescribing information, 2015) . The manufacturer also recommends that dabigatran should not be crushed or chewed, and that the pellets not be emptied from the capsule. This increases drug absorption and thus the risk of bleeding (Pradaxa (Dabigatran Etexilate Mesylate) prescribing information, 2015). Rivaroxaban and apixaban may be crushed for administration (Eliquis (Apixaban) prescribing information, 2015; Xarelto (Rivaroxaban) prescribing information, 2016). There is currently no data available on the bioavailability of edoxaban upon crushing (Edoxaban: Savaysa (Edoxaban) prescribing information, 2015). Rivaroxaban at higher doses of 15 or 20 mg should be administered with food. If taken when fasting, its bioavailability is reduced thereby resulting in possible under-anticoagulation (Xarelto (Rivaroxaban) prescribing information, 2016).
Incorrect dosing, storage, or improper administration of DOACs may result in either under-or over-anticoagulation. Furthermore, given that laboratory monitoring of DOACs is not routinely performed, it is essential to ensure that these medications are administrated appropriately. There are currently no available data on whether patients store or administer their DOACs properly. Therefore, we aimed to determine whether patients use their DOACs according to manufacturers' recommendations.
Adult patients (518 years) taking a DOAC for any indication were prospectively recruited at the Hamilton General Hospital. The study was approved by the Hamilton Integrated Research Ethics Board. Thrombosis Nurses at the Perioperative Anticoagulation Clinic helped patients complete a 12-item questionnaire, which included demographic data, most recent creatinine, DOAC dose and indication, DOAC prescriber, and length of time on DOAC. The questionnaire also sought information on whether DOACs were removed from packaging, how they were stored, administration with food, and pill crushing. The appropriateness of dose was assessed based on the indication, the patient's age, and creatinine clearance. The appropriateness of use was based on actual use compared to manufacturers' recommendations. Nurses flagged concerns about dose and/or use and communicated them to patients and referring physicians.
Ninety-three consecutive patients were recruited. Forty-nine were on dabigatran, 18 on apixaban, and 26 were on rivaroxaban. Baseline characteristics are listed in Table 1 . Sixty-two patients (67%) received appropriate DOAC dosing and administered the medication correctly. Eighteen patients (19%) administered the DOAC properly but at an inappropriate dose; 15 of these 18 patients (16%) received a dose that was too low and 3 (3%) a dose that was too high. Thirteen patients (14%) received an appropriate dose; however, they administered the DOAC inappropriately: 10 (11%) removed dabigatran from its packaging before administration (exposing it to moisture); 2 (2%) did not take rivaroxaban with food; and 1 (1%) crushed the dabigatran capsule. Multinomial logistic regression was performed. However, none of the variables including age, gender, creatinine clearance, or prescriber type influenced the appropriateness of dose or administration.
Our study has limitations. First, it is a cross-sectional patient report study, so the results may be subject to recall bias. Second, given that data on each patient was recorded once, it may be difficult to infer a temporal association between a risk factor and an outcome. Third, we did not assess the change in DOAC concentration or stability overtime. However, the results raise serious concerns around dosing and administration of DOACs, a widely prescribed class of drugs. This merits further exploration in a larger cohort study.
Data from our study demonstrate that there is a lack of patient education regarding DOAC administration and storage. This may result in under-or overanticoagulation of patients who require anticoagulation to prevent or treat life-threatening thrombosis. Our study highlights the vital role of nurses in improving patient's medication literacy and working with physicians to resolve dosing and administration errors. Further studies are needed to explore different education tools to improve patient and provider education around DOAC use. 
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